Analysis of serum anti-Müllerian hormone levels in the main phenotypes of polycystic ovary syndrome

doi:10.3969/j.issn.1006-7795.2016.04.006

Abstract

Abstract: Objective To analyze the serum anti-Müllerian hormone (AMH) levels, endocrine and metabolic characteristics in the main phenotypes of polycystic ovary syndrome (PCOS) groups and the controls, and evaluate the correlation between the AMH and these indicators. Methods A total of 174 PCOS cases were divided into four groups according to Rotterdam criteria and NIH recommendations, as follows:Group 1[polycystic ovary morphology (PCO) +oligo-anovulation (OA) +hyperandrogenism (HA)], Group 2 (PCO+OA), Group 3 (PCO+HA) and Group 4 (OA+HA). AMH, endocrine and metabolic levels were measured in serum. Results Serum anti-müllerian hormone levels:Group 1 (8.54±2.40) ng/mL > Group 2 (6.95±1.96) ng/mL > Group 3 (5.64±1.79) ng/mL > Group 4 (4.36±1.74) ng/mL > Controls (2.55±1.15) ng/mL. Conclusion AMH levels were higher in PCOS cases than in controls, with differences comparing the phenotypes. AMH levels correlate best with PCO. AMH has a positive correlation with the testosterone (T), number of follicles 2-9 mm and ovarian volume, has a negative correlation with estradiol (E2).

Key words: polycystic ovary syndrome, phenotype, anti-Müllerian hormone, polycystic ovary morphology

CLC Number:

R711.75

Wang Lijuan, Ruan Xiangyan, Cui Yamei, Zhao Yue, Du Juan, Li Yanglu, Yi Yingchun, Alfred O. Mueck. Analysis of serum anti-Müllerian hormone levels in the main phenotypes of polycystic ovary syndrome[J]. Journal of Capital Medical University, 2016, 37(4): 444-448.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2016.04.006

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2016/V37/I4/444

References

[1] 乔杰,李蓉,李莉,等.多囊卵巢综合征流行病学研究[J]. 中国实用妇科与产科杂志,2013,29(11):849-852.
[2] de Vet A, Laven J S, de Jong F H, et al.Antimullerian hormone serum levels: a putative marker for ovarian aging[J]. Fertil Steril, 2002, 77(2): 357-362.
[3] Siow Y, Kives S, Hertweck P, et al. Serum Mullerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome[J]. Fertil Steril, 2005, 84(4): 938-944.
[4] 熊紫薇,胡坚,陈薪宇,等. 抗缪勒氏管激素在多囊卵巢综合征诊断中的价值[J]. 分子影像学杂志,2015,38(2):80-83.
[5] Parahuleva N, Pehlivanov B, Orbecova M, et al. Anti-Mullerian hormone in the major phenotypes of polycystic ovary syndrome[J]. Akush Ginekol:Sofilia,2014,53(5):22-27.
[6] The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS)[J]. Hum Reprod, 2004, 19(1): 41-47.
[7] Salameh W A, Redor-Goldman M M, Clarke N J, et al. Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria [J]. Fertil Steril, 2014, 101(4): 1135-1141.
[8] Piouka A, Farmakiotis D, Katsikis I, et al. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels[J]. Am J Physiol Endocrinol Meetab, 2009, 296(2): E238-E243.
[9] Pigny P, Jonard S, Robert Y, et al. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2006, 91(3): 941-945.
[10] Pellatt L, Hanna L, Brincat M, et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries[J]. J Clin Endocrinol Metab, 2007, 92(1): 240-245.
[11] Lie Fong S, Visser J A, Welt C K, et al. Serum anti-müllerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood[J]. J Clin Endocrinol Metab, 2012, 97(12): 4650-4655.
[12] Dewailly D,Pigny P,Soudan B,et al. Reconciling the definitions of polycystic ovary syndrome the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism [J]. J Clin Endocrinol Metab,2010, 95(9): 4399-4405.
[13] 肖琳,李启富,唐良萏. PCOS患者血清抗苗勒管激素(AMH)水平与胰岛素抵抗及雄激素的关系[J]. 生殖与避孕,2011,31(7):488-490,494.
[14] Somunkiran A, Yavuz T, Yucel O, et al. Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome[J]. Eur J Obstet Gynecol Reprod Biol, 2007, 134 (2): 196-201.
[15] Barbakadze L, Kristasashvili J. Antimullerian hormone in cases of different reproductive pathologies[J]. Georgian Med News,2014, (232-233): 16-21.
[16] Cengiz H, Ekin M, Dagdeviren H, et al. Comparison of serum anti-müllerian hormone levels in normal weight and overweight-obese adolescent patients with polycystic ovary syndrome[J]. Eur J Obstet Gynecol Reprod Biol, 2014, 180: 46-50.
[17] Wiweko B, Maidarti M, Priangga M D, et al. Anti-mullerianhormone as a diagnostic and prognostic tool for PCOS patients[J]. J Assist Reprod Genet, 2014, 31(10): 1311-1316.
[18] Pierre A, Peigné M, Grynberg M, et al. Loss of LH-induced down-regulation of anti-Müllerianhormonereceptorexpression-maycontribute to anovulation in women with polycystic ovary syndrome[J]. Hum Reprod, 2013, 28(3): 762-769.
[19] Li J, Li R, Yu H, et al. The relationship between serum anti-Müllerian hormone levels and the follicular arrest forwomen with polycystic ovary syndrome[J]. Syst Biol Reprod Med, 2015,61(2): 103-109.
[20] 李莹,聂明月,方颖,等. 多囊卵巢综合征患者控制性超促排卵过程AMH和INHB浓度变化的临床研究[J]. 首都医科大学学报,2014,35(4):402-406.
[21] 卢永军,阮祥燕,田玄玄,等. 多囊卵巢综合征综合治疗疗效的评价[J]. 首都医科大学学报,2013,34(4):525-529.